Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

NCT00635089 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Esophagitis

Interventions

DRUG: reslizumab

Sponsor

Ception Therapeutics

Collaborators

[object Object]